Estimations des analystes de Wall Street pour REGENXBIO Inc. (RGNX): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Consensus des analystes
| Achat fort | 1 |
| Achat | 13 |
| Conserver | 5 |
| Vente | 1 |
| Vente forte | 0 |
| Analystes au total | 20 |
| Note moyenne (1-5) | 0.70 |
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-1.21 | ||
| 2026-08-06 | $0.43 | $0.08 | +446.2% |
| 2026-05-14 | $-1.72 | $-1.36 | -26.5% |
| 2026-03-05 | $-1.30 | $-1.01 | -28.7% |
| 2025-11-06 | $-1.20 | $-1.38 | +13.0% |
| 2025-08-07 | $-1.38 | $-1.13 | -22.1% |
| 2025-05-12 | $0.12 | $0.41 | -70.7% |
| 2025-03-13 | $-1.01 | $-1.27 | +20.5% |
Ratios de valorisation
| Prix / Valeur comptable | 5.87 |
| EV / EBITDA | -3.56 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $4.6M | $10.4M | $218.5M | $35.2M | $154.6M | $470.3M | $112.7M | $90.2M | $83.3M | $170.4M |
| Coût des Ventes | $959000 | $1.7M | $9.6M | $8.2M | $35.7M | $51.8M | $54.5M | $37.2M | $33.6M | $20.3M |
| Marge Brute | $3.6M | $8.7M | $208.9M | $27.0M | $118.9M | $418.5M | $58.2M | $53.0M | $49.8M | $150.1M |
| R&D | $45.5M | $57.2M | $83.9M | $124.2M | $166.3M | $181.4M | $242.5M | $232.3M | $208.5M | $228.3M |
| Frais Généraux | $23.6M | $27.2M | $36.9M | $51.8M | $63.8M | $79.3M | $85.3M | $88.5M | $76.6M | $82.9M |
| Charges Opérationnelles | $69.0M | $84.6M | $120.8M | $176.0M | $238.1M | $258.5M | $321.1M | $321.2M | $283.1M | $311.3M |
| Résultat Opérationnel | -$65.3M | -$75.9M | $88.1M | -$149.0M | -$119.2M | $160.0M | -$262.9M | -$268.1M | -$233.3M | -$161.2M |
| EBITDA | -$64.8M | -$73.2M | $92.1M | -$90.3M | -$96.8M | $177.1M | -$244.2M | -$239.5M | -$198.2M | -$133.3M |
| Charges d'Intérêt | 0 | 0 | 0 | 0 | $771000 | $26.3M | $23.3M | $6.9M | $12.7M | $45.0M |
| Résultat Avant Impôts | -$63.4M | -$73.2M | $104.1M | -$97.5M | -$106.0M | $141.2M | -$280.4M | -$263.6M | -$227.1M | -$193.9M |
| Impôts | -$435000 | $686000 | $4.2M | -$2.8M | $5.2M | $13.4M | -$84000 | -$152000 | 0 | 0 |
| Résultat Net | -$63.0M | -$73.2M | $99.9M | -$94.7M | -$111.2M | $127.8M | -$280.3M | -$263.5M | -$227.1M | -$193.9M |
| BPA | $-2.38 | $-2.45 | $2.73 | $-2.58 | $-2.98 | $3.01 | $-6.50 | $-6.02 | $-4.59 | $-3.76 |
| BPA Dilué | $-2.38 | $-2.45 | $2.73 | $-2.58 | $-2.98 | $2.91 | $-6.50 | $-6.02 | $-4.59 | $-3.76 |
| Actions en Circulation (Diluées) | $26.4M | $29.9M | $36.6M | $36.7M | $37.3M | $43.9M | $43.2M | $43.7M | $49.5M | $51.6M |
Prix
| Prix | $7.98 |
| Capitalisation | $413M |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: ABSI · CRVS · FDMT · GOSS · KALV · MLTX · OLMA
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de RGNX: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions